News stories about Alnylam Pharmaceuticals (NASDAQ:ALNY) have trended somewhat positive recently, Accern Sentiment reports. The research group rates the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Alnylam Pharmaceuticals earned a coverage optimism score of 0.22 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 46.9451761883996 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the news stories that may have impacted Accern’s analysis:
- Alnylam Pharmaceuticals (ALNY) Rating Increased to Buy at BidaskClub (americanbankingnews.com)
- Wired News – Alnylam Retains Global Rights for its Investigational RNAi Therapeutic Lumasiran (finance.yahoo.com)
- ALNYLAM PHARMACEUTICALS : to Report New Clinical Results from the APOLLO Phase 3 Study of Patisiran at the 16th International Symposium on Amyloidosis (4-traders.com)
- Alnylam to Report New Clinical Results from the APOLLO Phase 3 Study of Patisiran at the 16th International Symposium on Amyloidosis (finance.yahoo.com)
- Alnylam Pharmaceuticals, Inc. (ALNY) Director Philip A. Sharp Sells 15,000 Shares (americanbankingnews.com)
Several analysts recently commented on ALNY shares. Goldman Sachs Group raised shares of Alnylam Pharmaceuticals from a “buy” rating to a “conviction-buy” rating in a report on Friday, December 15th. Piper Jaffray Companies reissued a “buy” rating and issued a $182.00 price objective on shares of Alnylam Pharmaceuticals in a report on Sunday, January 7th. B. Riley reaffirmed a “buy” rating and set a $205.00 price target (down previously from $220.00) on shares of Alnylam Pharmaceuticals in a report on Monday, January 8th. Nomura upped their price target on shares of Alnylam Pharmaceuticals to $86.00 and gave the stock a “sell” rating in a report on Friday, February 9th. Finally, Morgan Stanley lowered their price objective on shares of Alnylam Pharmaceuticals from $128.00 to $118.00 and set an “equal weight” rating for the company in a research report on Friday, February 9th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $126.89.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, February 8th. The biopharmaceutical company reported ($1.48) earnings per share for the quarter, missing the consensus estimate of ($1.38) by ($0.10). Alnylam Pharmaceuticals had a negative return on equity of 41.08% and a negative net margin of 545.95%. The business had revenue of $37.90 million during the quarter, compared to analysts’ expectations of $19.31 million. During the same quarter in the previous year, the business earned ($1.32) EPS. Alnylam Pharmaceuticals’s revenue for the quarter was up 116.6% on a year-over-year basis. research analysts predict that Alnylam Pharmaceuticals will post -6.88 earnings per share for the current fiscal year.
In other Alnylam Pharmaceuticals news, SVP Laurie Keating sold 6,249 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Wednesday, December 20th. The shares were sold at an average price of $121.20, for a total transaction of $757,378.80. Following the completion of the sale, the senior vice president now directly owns 17,749 shares in the company, valued at $2,151,178.80. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Michael Mason sold 36,745 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Thursday, January 4th. The shares were sold at an average price of $131.59, for a total transaction of $4,835,274.55. Following the sale, the vice president now owns 6,352 shares of the company’s stock, valued at $835,859.68. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 57,994 shares of company stock valued at $7,527,653. 4.30% of the stock is currently owned by company insiders.
WARNING: This story was first posted by BBNS and is the sole property of of BBNS. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://baseballnewssource.com/2018/03/14/alnylam-pharmaceuticals-alny-given-daily-media-impact-score-of-0-22/1974598.html.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.